209 related articles for article (PubMed ID: 27624224)
1. Myelomatous Involvement of the Central Nervous System.
Paludo J; Painuly U; Kumar S; Gonsalves WI; Rajkumar V; Buadi F; Lacy MQ; Dispenzieri A; Kyle RA; Mauermann ML; McCurdy A; Dingli D; Go RS; Hayman SR; Leung N; Lust JA; Lin Y; Gertz MA; Kapoor P
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):644-654. PubMed ID: 27624224
[TBL] [Abstract][Full Text] [Related]
2. Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.
Abdallah AO; Atrash S; Shahid Z; Jameel M; Grazziutti M; Apewokin S; Kumar NS; Restrepo A; Waheed S; Van Rhee F; Heuck CJ; Johann D; Barlogie B; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):211-4. PubMed ID: 24373936
[TBL] [Abstract][Full Text] [Related]
3. Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Jurczyszyn A; Grzasko N; Gozzetti A; Czepiel J; Cerase A; Hungria V; Crusoe E; Silva Dias AL; Vij R; Fiala MA; Caers J; Rasche L; Nooka AK; Lonial S; Vesole DH; Philip S; Gangatharan S; Druzd-Sitek A; Walewski J; Corso A; Cocito F; Vekemans MC; Atilla E; Beksac M; Leleu X; Davila J; Badros A; Aneja E; Abildgaard N; Kastritis E; Fantl D; Schutz N; Pika T; Butrym A; Olszewska-Szopa M; Usnarska-Zubkiewicz L; Usmani SZ; Nahi H; Chim CS; Shustik C; Madry K; Lentzsch S; Swiderska A; Helbig G; Guzicka-Kazimierczak R; Lendvai N; Waage A; Andersen KT; Murakami H; Zweegman S; Castillo JJ
Am J Hematol; 2016 Jun; 91(6):575-80. PubMed ID: 26955792
[TBL] [Abstract][Full Text] [Related]
4. Myeloma of the central nervous system: association with high-risk chromosomal abnormalities, plasmablastic morphology and extramedullary manifestations.
Fassas AB; Muwalla F; Berryman T; Benramdane R; Joseph L; Anaissie E; Sethi R; Desikan R; Siegel D; Badros A; Toor A; Zangari M; Morris C; Angtuaco E; Mathew S; Wilson C; Hough A; Harik S; Barlogie B; Tricot G
Br J Haematol; 2002 Apr; 117(1):103-8. PubMed ID: 11918539
[TBL] [Abstract][Full Text] [Related]
5. Lack of survival improvement with novel anti-myeloma agents for patients with multiple myeloma and central nervous system involvement: the Greek Myeloma Study Group experience.
Katodritou E; Terpos E; Kastritis E; Delimpasis S; Symeonidis AS; Repousis P; Kyrtsonis MC; Vadikolia C; Michalis E; Polychronidou G; Michael M; Papadaki S; Papathanasiou M; Kokoviadou K; Kioumi A; Vlachaki E; Hadjiaggelidou C; Kouraklis A; Patsias I; Gavriatopoulou M; Kotsopoulou M; Verrou E; Gastari V; Christoulas D; Giannopoulou E; Pouli A; Konstantinidou P; Anagnostopoulos A; Dimopoulos MA
Ann Hematol; 2015 Dec; 94(12):2033-42. PubMed ID: 26420061
[TBL] [Abstract][Full Text] [Related]
6. Central nervous system multiple myeloma--potential roles for intrathecal therapy and measurement of cerebrospinal fluid light chains.
Lee D; Kalff A; Low M; Gangatharan S; Ho P; Bajel A; Ritchie D; Grigg A; Spencer A
Br J Haematol; 2013 Aug; 162(3):371-5. PubMed ID: 23718539
[TBL] [Abstract][Full Text] [Related]
7. Myelomatous meningitis evaluated by multiparameter flow cytometry : report of a case and review of the literature.
Marini A; Carulli G; Lari T; Buda G; Lambelet P; Ciancia EM; Benedetti E; Caracciolo F; Ferreri MI; Pesaresi I; Rousseau M; Ottaviano V; Azzarà A; Petrini M
J Clin Exp Hematop; 2014; 54(2):129-36. PubMed ID: 25318945
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Chen CI; Masih-Khan E; Jiang H; Rabea A; Cserti-Gazdewich C; Jimenez-Zepeda VH; Chu CM; Kukreti V; Trudel S; Tiedemann R; Tsang R; Reece DE
Br J Haematol; 2013 Aug; 162(4):483-8. PubMed ID: 23772701
[TBL] [Abstract][Full Text] [Related]
9. Overview of recent trends in diagnosis and management of leptomeningeal multiple myeloma.
Yellu MR; Engel JM; Ghose A; Onitilo AA
Hematol Oncol; 2016 Mar; 34(1):2-8. PubMed ID: 25524637
[TBL] [Abstract][Full Text] [Related]
10. Emergence of central nervous system myeloma in the era of novel agents.
Gangatharan SA; Carney DA; Prince HM; Wolf MM; Januszewicz EH; Ritchie DS; Harrison SJ
Hematol Oncol; 2012 Dec; 30(4):170-4. PubMed ID: 22144117
[TBL] [Abstract][Full Text] [Related]
11. Characterization of central nervous system multiple myeloma in the era of novel therapies.
Majd N; Wei X; Demopoulos A; Hormigo A; Chari A
Leuk Lymphoma; 2016 Jul; 57(7):1709-13. PubMed ID: 26727654
[No Abstract] [Full Text] [Related]
12. Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry.
Wudhikarn K; Bunworasate U; Julamanee J; Lekhakula A; Chuncharunee S; Niparuck P; Ekwattanakit S; Khuhapinant A; Norasetthada L; Nawarawong W; Makruasi N; Kanitsap N; Sirijerachai C; Chansung K; Wong P; Numbenjapon T; Prayongratana K; Suwanban T; Wongkhantee S; Praditsuktavorn P; Intragumtornchai T;
Ann Hematol; 2017 Jan; 96(1):57-64. PubMed ID: 27752821
[TBL] [Abstract][Full Text] [Related]
13. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
[TBL] [Abstract][Full Text] [Related]
14. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma.
Cote GM; Hochberg EP; Muzikansky A; Hochberg FH; Drappatz J; McAfee SL; Batchelor TT; LaCasce AS; Fisher DC; Abramson JS; Armand P; Chen YB
Biol Blood Marrow Transplant; 2012 Jan; 18(1):76-83. PubMed ID: 21749848
[TBL] [Abstract][Full Text] [Related]
15. Myelomatous involvement of the dura mater: a rare complication of multiple myeloma.
Roddie P; Collie D; Johnson P
J Clin Pathol; 2000 May; 53(5):398-9. PubMed ID: 10889825
[TBL] [Abstract][Full Text] [Related]
16. Blastic plasmacytoid dendritic cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy.
Martín-Martín L; Almeida J; Pomares H; González-Barca E; Bravo P; Giménez T; Heras C; Queizán JA; Pérez-Ceballos E; Martínez V; Alonso N; Calvo C; Álvarez R; Caballero MD; Orfao A
Oncotarget; 2016 Mar; 7(9):10174-81. PubMed ID: 26840087
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Lee MY; Kim HS; Lee JY; Lim SH; Kang ES; Ko YH; Kim SJ; Kim WS
Int J Hematol; 2015 Dec; 102(6):678-88. PubMed ID: 26493833
[TBL] [Abstract][Full Text] [Related]
18. Cerebral and meningeal multiple myeloma after autologous stem cell transplantation. A case report and review of the literature.
Petersen SL; Wagner A; Gimsing P
Am J Hematol; 1999 Dec; 62(4):228-33. PubMed ID: 10589078
[TBL] [Abstract][Full Text] [Related]
19. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review.
Kramer K; Kushner B; Heller G; Cheung NK
Cancer; 2001 Apr; 91(8):1510-9. PubMed ID: 11301399
[TBL] [Abstract][Full Text] [Related]
20. Imaging of extraosseous intracranial and intraspinal multiple myeloma, including central nervous system involvement.
Shpilberg KA; Esses SJ; Fowkes ME; Chari A; Sacher M; Naidich TP
Clin Imaging; 2015; 39(2):213-9. PubMed ID: 25547625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
